Ulcerative colitis is a chronic inflammatory bowel disease, disabling the lives of millions of people. The quality of life for moderate to severe ulcerative colitis patients is low with high incidence of anxiety, depression, unemployment and sick leave. Current treatment options have limited efficacy and problems with severe side effects. In addition, a substaintial proportion of patients with moderate to severe ulcerative colitis will not respond to available therapies or will eventually develop tolerance to treatment. For this patient group there is a high unmet medical need.
Cobitolimod is a first-in-class treatment with potential to relieve symptoms, induce mucosal healing and give seriously ill patients the opportunity to return to a normal life.
Cobitolimod has demonstrated clinical proof-of-concept for the treatment of moderate to severe active ulcerative colitis, showing statistically significant improvement of regulatory and clinically important endpoints.
High chance of success
Cobitolimod has, in addition to its clinical efficacy, a very favorable safety profile. A significant part of drugs in clinical development fail due to safety isseus. Cobitolimod is administrated locally with low systemic absorption, avoiding systemic toxicity and side effects, as well as providing a quick onset of action.